Related posts

Nervous markets await Nvidia
Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

NovoCure Limited, trading under the symbol NVCR-Q, has been viewed somewhat unfavorably by experts recently. Initially, the company's potential and offerings drew significant interest and support, but opinions have shifted as it has struggled to generate profits. An important concern among analysts is that the company's revenues have remained flat, indicating potential stagnation or operational challenges that need to be addressed. This lack of growth in revenue might raise red flags for investors seeking dynamic companies with robust financial performance. Overall, there's a sense of disappointment from experts who once had a favorable view of the company's prospects.

Consensus
Negative
Valuation
Overvalued
Similar
RGLD, RGLD
DON'T BUY

He used to like this company a lot, but they fail to make money. Revenues are flat.

BUY
The medical community doesn't recognize this company, but when it does the stock will double.
BUY
Recommended this in early-2018. Why has it doubled recently? It works. A friend of his used NVCR medical machines, and his life was extended by three years.
Showing 1 to 3 of 3 entries
  • «
  • 1
  • »

NovoCure Limited(NVCR-Q) Rating

Ranking : 3 out of 5

Star iconStar iconStar iconStar empty iconStar empty icon

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 1

Stockchase rating for NovoCure Limited is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

NovoCure Limited(NVCR-Q) Frequently Asked Questions

What is NovoCure Limited stock symbol?

NovoCure Limited is a American stock, trading under the symbol NVCR-Q on the NASDAQ (NVCR). It is usually referred to as NASDAQ:NVCR or NVCR-Q

Is NovoCure Limited a buy or a sell?

In the last year, 1 stock analyst published opinions about NVCR-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for NovoCure Limited.

Is NovoCure Limited a good investment or a top pick?

NovoCure Limited was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for NovoCure Limited.

Why is NovoCure Limited stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is NovoCure Limited worth watching?

1 stock analyst on Stockchase covered NovoCure Limited In the last year. It is a trending stock that is worth watching.

What is NovoCure Limited stock price?

On 2025-05-02, NovoCure Limited (NVCR-Q) stock closed at a price of $18.15.